3939-35-3Relevant academic research and scientific papers
The effect of hydrogen bonding and azomethine group orientation on liquid crystal properties in benzylidene aniline compounds
Kshash, Abdullah Hussein
, p. 739 - 747 (2020/10/02)
This study examines the effects of substituents and hydrogen bonding, orientations of imine linkage on the behavior of benzylidene aniline compounds as liquid crystals (LC). Compounds 4-carboxy benzylidene-4-X-aniline (X = H, F, Cl, Br, CH3, OCH3) 1a-6a were synthesized by the reaction of aniline and its substituted derivatives with 4-formylbenzoic acid. Compounds 4-X-benzylidene-4-carboxy aniline (X = H, F, Cl, Br, CH3, OCH3) 1b-6b were synthesized by the reaction of benzaldehyde and its substituted derivatives with 4-aminobenzoic acid using absolute ethanol as the solvent. Synthesized compounds were characterized by FT IR and 1H NMR spectroscopy, liquid crystal properties were investigated using differential scanning calorimetry (DSC) and polarizing optical microscopy (POM) techniques. Based on the mesomorphic properties, it was proven that the compounds 2b-4b are dimorphic exhibiting a smectic and nematic phase, compounds 5b, 6b are monomorphic exhibiting a nematic phase, while compounds 1a-6a and 1b have not shown any mesophase. For compounds 1a-6a hydrogen bonding and reversing imine linkage (in comparison with compounds 1b-6b) caused the absence of their mesomorphic properties.
Human glucagon receptor antagonists with thiazole cores. A novel series with superior pharmacokinetic properties
Madsen, Peter,Kodra, János T.,Behrens, Carsten,Nishimura, Erica,Jeppesen, Claus B.,Pridal, Lone,Andersen, Birgitte,Knudsen, Lotte B.,Valcarce-Aspegren, Carmen,Guldbrandt, Mette,Christensen, Inge T.,J?rgensen, Anker S.,Ynddal, Lars,Brand, Christian L.,Bagger, Morten Aa.,Lau, Jesper
experimental part, p. 2989 - 3000 (2010/02/28)
The aim of the work presented here was to design and synthesize potent human glucagon receptor antagonists with improved pharmacokinetic (PK) properties for development of pharmaceuticals for the treatment of type 2 diabetes. We describe the preparation of compounds with cyclic cores (5-aminothiazoles), their binding affinities for the human glucagon and GIP receptors, as well as affinities for rat, mouse, pig, dog, and monkey glucagon receptors. Generally, the compounds had slightly less glucagon receptor affinity compared to compounds of the previous series, but this was compensated for by much improved PK profiles in both rats and dogs with high oral bioavailabilities and sustained high plasma exposures. The compounds generally showed species selectivity for glucagon receptor binding with poor affinities for the rat, mouse, rabbit, and pig receptors. However, dog and monkey glucagon receptor affinities seem to reflect the human situation. One compound of this series, 18, was tested intravenously in an anesthetized glucagon-challenged monkey model of hyperglucagonaemia and hyperglycaemia and was shown dose-dependently to decrease glycaemia. Further, high plasma exposures and a long plasma half-life (5.2 h) were obtained.
